Trials / Terminated
TerminatedNCT01353963
Desvenlafaxine Succinate (Pristiq): Postmarketing Surveillance Study Among Filipino Patients
An Open Label, Non-interventional Study Of The Safety Of Desvenlafaxine Succinate (Pristiq) In The Treatment Of Major Depressive Disorder (Mdd) And Vasomotor Symptoms (Vms) Associated With Menopause In Filipino Adult Patients: A Post Marketing Surveillance Study
- Status
- Terminated
- Phase
- —
- Study type
- Observational
- Enrollment
- 13 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a non-interventional study to review safety data on administration of desvenlafaxine succinate among Filipino patients with MDD and VMS per usual clinical practice within the first three years post commercial distribution.
Detailed description
post marketing surveillance none
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | desvenlafaxine succinate | 50 mg tablet once daily |
Timeline
- Start date
- 2012-03-01
- Primary completion
- 2012-08-01
- Completion
- 2012-08-01
- First posted
- 2011-05-16
- Last updated
- 2016-01-18
- Results posted
- 2016-01-18
Locations
3 sites across 1 country: Philippines
Source: ClinicalTrials.gov record NCT01353963. Inclusion in this directory is not an endorsement.